RECRUITING

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Official Title

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

Quick Facts

Study Start:2021-09-02
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04218409

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals fluent in English will participate.
  2. * Must report recreational use of opioids.
  3. * Be within 20% of their ideal body weight.
  4. * Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  5. * Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  6. * Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.
  1. * Significant current physical disease or major psychiatric disorder.
  2. * No self-reported current interest in drug abuse treatment.
  3. * Women who are pregnant or nursing.
  4. * Any comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.
  5. * Any conditions that preclude safety in the MRI scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is MRI safe), and claustrophobia.

Contacts and Locations

Study Contact

Lauren Nieder
CONTACT
352-294-1067
lauren.nieder@ufl.edu

Principal Investigator

Meredith Berry, PhD
PRINCIPAL_INVESTIGATOR
University of Florida

Study Locations (Sites)

University of Florida
Gainesville, Florida, 32611
United States

Collaborators and Investigators

Sponsor: University of Florida

  • Meredith Berry, PhD, PRINCIPAL_INVESTIGATOR, University of Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-02
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2021-09-02
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Pain